The National Committee on IP Rights of the Philippines prevented more than PHP455 million worth of counterfeit medicines and personal care products from reaching consumers in the first seven months of this year.
The US House Committee on Energy & Commerce has voted to advance a drug pricing plan which would lower the cost of many prescription drugs.
Actavis Laboratories cannot market a generic version of Horizon Pharma’s knee pain treatment, an appeals court has ruled.
Johnson & Johnson has committed $500 million to research and development programmes over the next four years in a bid to eliminate HIV and tuberculosis across the world by 2030.
California has become the first US state to ban pay-for-delay deals in the pharmaceutical industry.
The English High Court has sided with pharmaceutical company Vectura and Novartis-owned Sandoz in a passing off lawsuit brought by rival GSK.
The US Court of Appeals for the Federal Circuit last week reversed a Patent Trial and Appeal Board decision, which found that claims in an OSI Pharmaceuticals patent for cancer treatment were obvious.
Canadian pharmaceutical company Bausch Health is suing Sandoz for patent infringement over its notice of intent to release a generic version of Xifaxan, Bausch’s irritable bowel syndrome drug.
The US Food and Drug Administration and Drug Enforcement Administration have issued joint warning letters to four online networks which allegedly sell unapproved and misbranded versions of medicines.
An independent parliamentary report has today, September 27, revealed that the UK’s health ministry remains unsure whether the country’s health service can fully withstand the impact of a no-deal Brexit next month.